A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis
Part of paid clinical trials in Dothan, Alabama.
- Sponsor
- Enanta Pharmaceuticals, Inc
- Study ID
- NCT03394924
- Phase
- PHASE2
- Status
- Completed
Conditions
- Primary Biliary Cholangitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- EDP-305 1 mg — DRUGTwo tablets daily for 12 weeks
- EDP-305 2.5 mg — DRUGTwo tablets daily for 12 weeks
- Placebo — DRUGTwo tablets daily for 12 weeks
Study Details
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with primary biliary cholangitis
Key Dates
- First listed
- Jan 9, 2018
- Start date
- Dec 27, 2017
- Status verified
- Jun 2020
- Primary completion
- Dec 19, 2019
- Completion
- Jan 16, 2020
Study Design
- Enrollment
- 68 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: EDP-305 1 mgSubjects will take 2 tablets once a day orally for 12 weeks
- Experimental: EDP-305 2.5 mgSubjects will take 2 tablets once a day orally for 12 weeks
- Placebo Comparator: PlaceboSubjects will take two tablets once a day orally for 12 weeks
Primary Outcome Measure
Percentage of Participants With At Least a 20% Reduction in Alkaline Phosphatase (ALP) or Normalization of ALP at Week 12 Compared to Baseline [ Time Frame: Baseline and Week 12 ]
Locations (40)
Find similar trials in Dothan, AL
By research site
Related Studies
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisPHASE2 · Recruiting · Mirum Pharmaceuticals, Inc. · Los Angeles, California
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisPHASE3 · Recruiting · Gilead Sciences · Birmingham, Alabama
- A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing TreatmentRecruiting · Ipsen · Coronado, California
- Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical OutcomesPHASE3 · Recruiting · Zydus Therapeutics Inc. · Marietta, Georgia